Global Auto-Injectors Market, by Product Type (Prefilled Auto-injectors, Fillable Auto-injectors), by Disease Indication (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others (Diabetes, Psoriasis, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4,497.7 Million in 2022 and is expected to exhibit a CAGR of 18.0% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing adoption of inorganic strategies by market players such as product approval by regulatory authorities such as European Commission (EC) is expected to drive the market growth over the forecast period. For instance, in February 2021, Xeris Biopharma Holdings, Inc., a biopharmaceutical company, announced that they had received an approval from European Commission for Ogluo (glucagon) injection. Ogluo, the first pre-mixed auto-injector used for the treatment of severe hypoglycemia, in adults and children aged 2 years and over with diabetes mellitus.
Global Auto-injectors Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global auto-injectors market, owing to the increasing demand for supply of auto-injectors. For instance, in September 2022, according to the data published by Centers for Disease Control and Prevention, anaphylaxis which is an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination. Hence, for the management of anaphylaxis, prefilled syringe and auto-injector should be available at the vaccination location at all times which increases the demand for the supply of auto-injectors.
Global Auto-injectors Market: Key Developments
In January 2021, Takeda Pharmaceutical Company Limited., a pharmaceutical company, announced that they had received an approval from Health Canada for ENTYVIO (vedolizumab). ENTYVIO is self-injectable subcutaneous formulation for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis.
Browse 37 Market Data Tables and 35 Figures spread through 170 Pages and in-depth TOC on “Global Auto-injectors Market”- Forecast to 2030, Global Auto-injectors Market, by Product Type (Prefilled Auto-injectors, Fillable Auto-injectors), by Disease Indication (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others (Diabetes, Psoriasis, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/auto-injectors-market-1035
Moreover, increasing number of inorganic strategies such as patent approval is expected to drive the global auto-injectors market over the forecast period. For instance, in March 2022, BlackHagen Design, a multidisciplinary, user-research, and product design firm, announced that they have received patent approval for miniaturized auto-injector design. This small auto-injector technology will provide different volumetric capabilities ranging from 25 mm3 to 2,500 mm3 for drug dosing.
Key Takeaways of the Global Auto-injectors Market:
- The global auto-injectors market is expected to exhibit a CAGR of 18.0% during the forecast period due to the increasing adoption of strategies such as product approval by the key market players. For instance, in June 2019, GSK plc., a healthcare company, announced that they had received an approval from U.S. Food and Drug Administration for Nucala (mepolizumab), an auto-injector and a pre-filled safety syringe. This is the first anti-IL5 biologic to be licensed in the US for self-administration, and the first respiratory biologic to be approved for administration via an auto-injector.
- Among product type, prefilled auto-injector segment is estimated to hold a dominant position in the global auto-injectors market over the forecast period. For instance, in November 2018, Genentech, Inc., a biotechnology company, announced that they had received an approval from U.S. Food and Drug Administration for ACTPen, the Actemra auto-injector. It is a single-dose prefilled auto-injector used for the treatment of moderate to severe active rheumatoid arthritis (RA) in the adult patients
- Among regions, North America is estimated to account for the largest market share in the global auto-injectors market, owing to the increasing product launch in the U.S. by key market players. For instance, in August 2019, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced that they had launched epinephrine auto-injector which is a generic version of EpiPen Jr auto-injector in the US. Epinephrine injection is a prefilled auto-injector used to treat life-threatening, allergic emergencies including anaphylaxis
- Major players operating in the global auto-injectors market include Becton, Dickinson and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Xeris Biopharma Holdings Inc., BlackHagen Design, GSK plc., Genentech, Inc., AstraZeneca, Owen Mumford Ltd., Stevanato Group, Jabil Inc., Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Pharmaceuticals, Inc., Antares Pharma, Eli Lilly and Company, Amgen Inc., Rafa Laboratories Ltd., Halozyme, Inc., Biogen, and Teva Pharmaceutical Industries Ltd.
